title: Peripheral blood lymphocyte dynamics and viral kinetics in patients with chronic active hepatitis B virus infection treated by tenofovir.
abstract: OBJECTIVE
  We investigated serum viral kinetics and peripheral blood lymphocyte dynamics in chronic hepatitis B patients during the first year of tenofovir therapy.
  
  
  METHODS
  Fifteen patients, naive to any kind of previous antiviral therapy, were included in this study. The patients received tenofovir daily 245mg for 48 weeks. Fifteen age and gender compatible healthy subjects were enrolled as the control group. Clinical, biochemical, immunological and virological parameters were assessed at baseline, then at the first, third, sixth and twelfth months.
  
  
  RESULTS
  CD4+CD25+FOXP3+ nTregs percentages were significantly higher in the study group than that of healthy controls, CD4+CD28+ and CD4+CD38+ T cell percentages were significantly lower in the study group than those of control group (p<0.001). Twelve cases had undetectable HBV DNA levels after the one year therapy. We determined that there was an increase of the CD28+co-stimulator molecule on both the CD4+ and CD8+ T cells while a decrease of the CD8+CD38+ T cells, CD4+CD38+ T cells and CD4+CD25+FOXP3+ nTregs, in patients with tenofovir treatment, but only CD4+CD25+FOXP3+ nTregs were statistically significant.
  
  
  CONCLUSIONS
  We found that both viral load and CD4+CD25+FOXP3+ nTreg percentages decreased significantly in patients with chronic hepatitis B virus infection during 1 year course of tenofovir treatment.
authors.affiliation: Department of Immunology, Zonguldak Karaelmas University School of Medicine, Kozlu-Zonguldak, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Arasli
authors.forename: Yucel
authors.initials: Y
authors.lastname: Ustundag
authors.forename: Basak
authors.initials: B
authors.lastname: Delikanli
authors.forename: Ferda
authors.initials: F
authors.lastname: Harmandar
authors.forename: Cagatay
authors.initials: C
authors.lastname: Buyukuysal
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000097:blood; D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D018106:CD28 Antigens / Q000097:blood; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000821:virology; D004279:DNA, Viral / Q000097:blood; D005260:Female; D005434:Flow Cytometry; D051858:Forkhead Transcription Factors / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood; D007700:Kinetics; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology / Q000821:virology; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects / Q000276:immunology / Q000821:virology; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology / Q000821:virology; D000068698:Tenofovir; D016896:Treatment Outcome; D014421:Turkey; D019562:Viral Load; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D018106:CD28 Antigens; D004279:DNA, Viral; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; C508017:IL2RA protein, human; D053645:Interleukin-2 Receptor alpha Subunit; D008562:Membrane Glycoproteins; D063065:Organophosphonates; D000068698:Tenofovir; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1; D000225:Adenine